UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 24, 2021

 


 

Aravive, Inc.

(Exact name of Registrant as Specified in Its Charter)

 


 

Delaware  001-36361 26-4106690
(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

                 

River Oaks Tower

3730 Kirby Drive, Suite 1200

Houston, Texas 77098

(Address of principal executive offices)

 

(936) 355-1910

(Registrants telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading

Symbol(s)

  Name of each exchange on which registered
Common stock, par value $0.0001 per share   ARAV   Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 



 

 

 

Item 7.01.   Regulation FD Disclosure.

 

On June 24, 2021, Aravive, Inc. (the “Company”) issued a press release announcing positive initial results from the Phase 1b portion of its Phase 1b/2 study in patients dosed with 15mg/kg of AVB-500 in combination with Cabozantinib in clear cell renal cell carcinoma. The data in three evaluable patients showed that AVB-500 was well tolerated with no unexpected findings. The Company also announced plans to expand the dosing of 15mg/kg of AVB-500 in an additional three patients to determine the potential of initiating the Phase 2 portion with this dose.

 

The information in this Item 7.01, in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

The press release furnished as Exhibit 99.1 to this Current Report on Form 8-K includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are “forward-looking” rather than historical.

 

The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time if its management believes it is appropriate. Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press releases or through other public disclosures.

 

Item 8.01.   Other Events. 

 

On June 24, 2021, the Company issued a press release announcing positive initial results from the Phase 1b portion of its Phase 1b/2 study in patients dosed with 15mg/kg of AVB-500 in combination with Cabozantinib in clear cell renal cell carcinoma. The data in three evaluable patients showed that AVB-500 was well tolerated with no unexpected findings. The Company also announced plans to expand the dosing of 15mg/kg of AVB-500 in an additional three patients to determine the potential of initiating the Phase 2 portion with this dose.

 

Item 9.01.   Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibit is furnished to this Current Report on Form 8-K:

 

Exhibit

Number

 

Description

99.1

 

Press Release

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date: June 24, 2021

ARAVIVE, INC.

(Registrant)

   
 

By:

 

/s/ Gail McIntyre           

 

Name:

 

Gail McIntyre

 

Title:

 

Chief Executive Officer

 

 

 
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Oct 2021 to Nov 2021 Click Here for more Aravive Charts.
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Nov 2020 to Nov 2021 Click Here for more Aravive Charts.